Cubist Pharmaceuticals Inc
Most Recent
Understanding Johnson & Johnson’s Growth Strategies
Johnson & Johnson (JNJ) is working on various organic and inorganic growth strategies in order to maintain its position as a leading pharmaceutical company worldwide.
Elliott Management exits position in Covidien
In January 2015, Medtronic (MDT) completed the acquisition of Covidien (COV). The cash and stock transaction was valued at approximately $49.9 billion.
Elliott Management starts new position in Cubist Pharmaceuticals
Cubist Pharmaceuticals has grown its pipeline via acquisitions. In 2013, it acquired Trius Therapeutics, obtaining rights to tedizolid phosphate.
Elliott Management discloses 4Q14 positions
Elliott Management, a New York–based hedge fund, disclosed new positions in a 13F filed last month. Elliott Management has over 83 stocks in its portfolio.
Must-know: Why Maverick adds new position in Ashland
Ashland has seen pressure from activist investor JANA Partners, which acquired a stake in the chemical maker in April, 2013, to boost shareholder value.
Must-know: Lee Ainslie and Maverick Capital’s 1Q14 positions
The fund’s portfolio decreased slightly from $7.73 billion to $7.14 billion in the first quarter.